Log in
(Ad)
Want to know which stocks should be on your radar this week? Every Sunday we send out the 3 Stock Trades that we predict will be big winners for the week ahead.

NYSEAMERICAN:NBY - NovaBay Pharmaceuticals Stock Price, Forecast & News

$0.63
+0.01 (+1.62 %)
(As of 01/21/2020 07:42 AM ET)
Today's Range
$0.61
Now: $0.63
$0.64
50-Day Range
$0.45
MA: $0.68
$1.20
52-Week Range
$0.23
Now: $0.63
$4.04
Volume223,907 shs
Average Volume240,117 shs
Market Capitalization$17.53 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:NBY
CUSIPN/A
Phone+1-510-8998800

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees70
Market Cap$17.53 million
Next Earnings Date3/26/2020 (Estimated)
OptionableNot Optionable

Receive NBY News and Ratings via Email

Sign-up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter.


(Ad)


Each week, an exclusive group of investors receives access to a simple list of 3 stocks to put on their radar for the week ahead.

You can sign up today to receive access to next week's watchlist -- generated by a proprietary methodology -- at no cost or obligation.

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Frequently Asked Questions

What is NovaBay Pharmaceuticals' stock symbol?

NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NBY."

When did NovaBay Pharmaceuticals' stock split? How did NovaBay Pharmaceuticals' stock split work?

NovaBay Pharmaceuticals's stock reverse split on the morning of Monday, December 21st 2015. The 1-25 reverse split was announced on Friday, December 11th 2015. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 18th 2015. An investor that had 100 shares of NovaBay Pharmaceuticals stock prior to the reverse split would have 4 shares after the split.

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) issued its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.02) EPS for the quarter. The biopharmaceutical company had revenue of $1.62 million for the quarter. View NovaBay Pharmaceuticals' Earnings History.

When is NovaBay Pharmaceuticals' next earnings date?

NovaBay Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for NovaBay Pharmaceuticals.

What guidance has NovaBay Pharmaceuticals issued on next quarter's earnings?

NovaBay Pharmaceuticals issued an update on its FY 2019 After-Hours earnings guidance on Monday, November, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $$6-8 million, compared to the consensus revenue estimate of $$7.65 million.

What price target have analysts set for NBY?

3 brokerages have issued 1-year price targets for NovaBay Pharmaceuticals' shares. Their forecasts range from $1.10 to $1.10. On average, they expect NovaBay Pharmaceuticals' stock price to reach $1.10 in the next year. This suggests a possible upside of 75.1% from the stock's current price. View Analyst Price Targets for NovaBay Pharmaceuticals.

What is the consensus analysts' recommendation for NovaBay Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovaBay Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NovaBay Pharmaceuticals.

Has NovaBay Pharmaceuticals been receiving favorable news coverage?

Media stories about NBY stock have trended extremely negative recently, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. NovaBay Pharmaceuticals earned a daily sentiment score of -4.0 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for NovaBay Pharmaceuticals.

Are investors shorting NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals saw a decline in short interest during the month of December. As of December 31st, there was short interest totalling 513,700 shares, a decline of 18.1% from the December 15th total of 627,200 shares. Based on an average daily volume of 528,200 shares, the short-interest ratio is presently 1.0 days. Approximately 3.2% of the shares of the stock are short sold. View NovaBay Pharmaceuticals' Current Options Chain.

Who are some of NovaBay Pharmaceuticals' key competitors?

What other stocks do shareholders of NovaBay Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include Opko Health (OPK), Achillion Pharmaceuticals (ACHN), AEterna Zentaris (AEZS), Catalyst Pharmaceuticals (CPRX), CorMedix (CRMD), SLS International (SLS), Arbutus Biopharma (ABUS), Agenus (AGEN), Amarin (AMRN) and AVEO Pharmaceuticals (AVEO).

Who are NovaBay Pharmaceuticals' key executives?

NovaBay Pharmaceuticals' management team includes the folowing people:
  • Mr. Justin M. Hall, Interim Pres, CEO, Gen. Counsel & Corp. Sec. (Age 41)
  • Mr. Jason Philip Raleigh, Interim CFO, Treasurer & Corp. Controller (Age 42)
  • Dr. David W. Stroman, Sr. VP of Ophthalmic Product Devel. & Chair of Ophthalmology Advisory Board (Age 74)

How do I buy shares of NovaBay Pharmaceuticals?

Shares of NBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is NovaBay Pharmaceuticals' stock price today?

One share of NBY stock can currently be purchased for approximately $0.63.

How big of a company is NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals has a market capitalization of $17.53 million. NovaBay Pharmaceuticals employs 70 workers across the globe.View Additional Information About NovaBay Pharmaceuticals.

What is NovaBay Pharmaceuticals' official website?

The official website for NovaBay Pharmaceuticals is http://novabay.com/.

How can I contact NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals' mailing address is 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States. The biopharmaceutical company can be reached via phone at +1-510-8998800.


MarketBeat Community Rating for NovaBay Pharmaceuticals (NYSEAMERICAN NBY)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  219 (Vote Outperform)
Underperform Votes:  193 (Vote Underperform)
Total Votes:  412
MarketBeat's community ratings are surveys of what our community members think about NovaBay Pharmaceuticals and other stocks. Vote "Outperform" if you believe NBY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2020 by MarketBeat.com Staff

Featured Article: Growth Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel